Showing 2451-2460 of 5623 results for "".
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Unity Biotechnology Presents Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseaseshttps://modernod.com/news/unity-biotechnology-presents-data-demonstrating-improvement-in-retinal-vasculature-and-function-in-preclinical-models-of-diabetic-retinopathy-eye-diseases/2479156/Unity Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectivel
- Pfizer, BioNTech Seek EU Nod to Allow COVID-19 Vaccine Use in Younger Teenshttps://modernod.com/news/pfizer-biontech-seek-eu-nod-to-allow-covid-19-vaccine-use-in-younger-teens/2479158/Pfizer and BioNTech said they have asked the European Medicines Agency (EMA) to extend the conditional marketing authorization for their COVID-19 vaccine Comirnaty to adolescents 12 to 15 years of age. The companies recently made a similar request to the FDA for the vaccine, which is already auth
- Refractive Surgery Council Reports Nearly 30% Rise in Laser Vision Correction Procedures Year over Yearhttps://modernod.com/news/refractive-surgery-council-reports-nearly-30-rise-in-laser-vision-correction-procedures-year-over-year/2479148/The Refractive Surgery Council (RSC), which helps consumers make informed choices about their vision correction options, reported a strong start to 2021 with a nearly 30 percent rise in laser vision correction (LVC) procedures year over year. More than 220,000 LASIK, SMILE and PRK procedures hav
- Ophthalmic World Leaders Announces Development and Networking Program for Executives Seeking Corporate Board Positionshttps://modernod.com/news/ophthalmic-world-leaders-announces-development-and-networking-program-for-executives-seeking-corporate-board-positions/2479130/Ophthalmic World Leaders (OWL) has announced its inaugural “Get-On-Board with OWL” program. Primarily aimed at executive-level women and underrepresented communities, this new offering will help attendees develop the skills and connections required to secure board positions in a rapid
- Eyemate System for Remote Glaucoma Management Obtains FDA Breakthrough Device Designationhttps://modernod.com/news/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation/2479126/Implandata Ophthalmic Products announced today that its Eyemate system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the US FDA. A BDD is only assigned for breakthrough technologies that have the potential to pro
- Amydis Completes Pre-IND Meeting With the FDA for the Development of a Retinal Tracer for the Diagnosis of Alpha-Synucleinopathieshttps://modernod.com/news/amydis-completes-pre-ind-meeting-with-the-fda-for-the-development-of-a-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/2479113/Amydis announced completion of pre-Investigational New Drug (IND) interaction with the FDA regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies (ASYN). Funding provided by The Michael J. Fox Foundation for Parkinson’s
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- RETINA-AI Health Awarded US Patent for AI Detection of Eye Diseasehttps://modernod.com/news/retina-ai-health-awarded-us-patent-for-ai-detection-of-eye-disease/2479088/RETINA-AI Health has been awarded a US patent on its artificial intelligence (AI) systems for autonomous detection of eye diseases from images. There are several eye diseases such as diabetic retinopathy, macular degeneration, and glaucoma for which segments of the general population need to be r